BRIEF-Arbutus Receives Regulatory Approval To Initiate A Phase 1A/1B Clinical Trial With AB-836, An Oral Capsid Inhibitor For The Treatment Of Chronic Hepatitis B Infection

March 16 (Reuters) - Arbutus Biopharma Corp ABUS.O:

• ARBUTUS RECEIVES REGULATORY APPROVAL TO INITIATE A PHASE 1A/1B CLINICAL TRIAL WITH AB-836, AN ORAL CAPSID INHIBITOR FOR THE TREATMENT OF CHRONIC HEPATITIS B INFECTION

Source text for Eikon: ID:nGNXZqry8

Further company coverage: ABUS.O

((Reuters.Briefs@thomsonreuters.com;))